Meeting
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
Authors
Jasmine Huynh
UC Davis Comprehensive Cancer Center, Sacramento, CA
Jasmine Huynh , Justin Chen , Edward Jae-Hoon Kim , David R. Gandara , Thomas John Semrad , Jonathan W. Riess , Tianhong Li , Chun-Yi Wu , Chao Zhang , Aiming Yu , Karen Matsukuma , Karen Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT01924260
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3589)
DOI
10.1200/JCO.2020.38.15_suppl.3589
Abstract #
3589
Poster Bd #
319
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Edward Jae-hoon Kim
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2023 ASCO Annual Meeting
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
First Author: Chia-Chi Lin
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt